Baloxavir Marboxil: An Original New Drug against Influenza

被引：30

作者：

Dufrasne, Francois ^{[1
]}

机构：

[1] Univ Libre Bruxelles, Unite Microbiol Chim Bioorgan & Macromol, Dept Rech & Dev Medicament, Fac Pharm, Campus Plaine CP 205-5, B-1050 Brussels, Belgium

来源：

PHARMACEUTICALS | 2022年 / 15卷 / 01期

关键词：

baloxavir marboxil; influenza; baloxavir acid; prodrug; cap-dependent endonuclease; Xofluza; VIRUS; OSELTAMIVIR; INHIBITORS; OUTCOMES;

D O I：

10.3390/ph15010028

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the biologically active baloxavir acid. This new medicine has been marketed in Japan, the USA and Europe. It is well tolerated (more than 1% of the patients experienced diarrhea, bronchitis, nausea, nasopharyngitis, and headache), and both influenza A and B viruses are sensitive, although the B strain is more resistant due to variations in the amino acid residues in the binding site. The drug is now in post-marketing pharmacovigilance phase, and its interest will be especially re-evaluated in the future during the annual flu outbreaks. It has been also introduced in a recent clinical trial against COVID-19 with favipiravir.

引用

页数：11

共 29 条

[1] Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season [J].

Chong, Yong ;

Kawai, Naoki ;

Tani, Naoki ;

Bando, Takuma ;

Takasaki, Yoshio ;

Shindo, Shizuo ;

Ikematsu, Hideyuki .

ANTIVIRAL RESEARCH, 2021, 192

[2] Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults. Author's reply [J].

de Haas, Esther C. ;

Luijendijk, Hendrika J. .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2020, 72 :102-102

[3] Baloxavir for influenza: Enrichment obscured lack of effect in North-American adults [J].

de Haas, Esther C. ;

Luijendijk, Hendrika J. .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 62 :E8-E9

[4] Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection [J].

Fukao, Keita ;

Noshi, Takeshi ;

Yamamoto, Atsuko ;

Kitano, Mitsutaka ;

Ando, Yoshinori ;

Noda, Takahiro ;

Baba, Kaoru ;

Matsumoto, Kazumi ;

Higuchi, Naoko ;

Ikeda, Minoru ;

Shishido, Takao ;

Naito, Akira .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (03) :654-662

[5] Sixty seconds on ... baloxavir [J].

Hawkes, Nigel .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 363

[6] Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents [J].

Hayden, Frederick G. ;

Sugaya, Norio ;

Hirotsu, Nobuo ;

Lee, Nelson ;

de Jong, Menno D. ;

Hurt, Aeron C. ;

Ishida, Tadashi ;

Sekino, Hisakuni ;

Yamada, Kota ;

Portsmouth, Simon ;

Kawaguchi, Keiko ;

Shishido, Takao ;

Arai, Masatsugu ;

Tsuchiya, Kenji ;

Uehara, Takeki ;

Watanabe, Akira .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10) :913-923

[7] Baloxavir: First Global Approval [J].

Heo, Young-A .

DRUGS, 2018, 78 (06) :693-697

[8] Influenza Virus: A Master Tactician in Innate Immune Evasion and Novel Therapeutic Interventions [J].

Hsu, Alan Chen-Yu .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[9] Review of the Patent Literature: Synthesis and Final Forms of Antiviral Drugs Tecovirimat and Baloxavir Marboxil [J].

Hughes, David L. .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (07) :1298-1307

[10]

Ishiguro N, 2021, BMC INFECT DIS, V21, DOI [10.1186/s12879-021-06494-w, 10.1186/s12879-021-06602-w]

← 1 2 3 →